🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. MD-1100 Acetate

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome

    phase 2 small molecule completed

    1 trial

  2. MD-1100 Acetate

    IRONWOOD PHARMACEUTICALS INC

    Constipation

    phase 2 small molecule completed

    1 trial

  3. MD-7246

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome With Diarrhea (IBS-D)

    phase 2 small molecule completed

    1 trial

  4. MEDI0618, Placebo to match MEDI0618

    AbbVie Deutschland GmbH & Co. KG

    Migraine

    phase 2 small molecule active

    1 trial

  5. METFORMIN , Placebo 515

    Pari Pharma GmbH

    Portal hypertension (PHT) and consequences in complications of cirrhosis

    phase 2 small molecule active

    1 trial

  6. METFORMIN , The placebo components are propylene glycol, neoPCLO/W, fenonip XB and purified water., METHYL AMINOLEVULINATE

    The George Institute

    Actinic keratoses

    phase 2 small molecule active

    1 trial

  7. MGL-3196

    Madrigal Pharmaceuticals EU Limited

    Non-alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  8. MGL-3196 (resmetirom)

    Madrigal Pharmaceuticals EU Limited

    Heterozygous Familial Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

  9. MHS-1031

    CATALYST PHARMACEUTICALS, INC.

    Gastroesophageal Reflux

    phase 2 small molecule active

    1 trial

  10. MK-2060, Placebo to MK-2060

    Merck Sharp and Dohme

    Prevention of arteriovenous graft thrombosis

    phase 2 small molecule active

    1 trial

  11. MK-2214, Florquinitau F18, Placebo to MK-2214

    Merck Sharp and Dohme

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  12. MKC-1

    CASI Pharmaceuticals

    Advanced Cancer

    phase 2 small molecule completed

    2 trials

  13. MKC-1

    CASI Pharmaceuticals

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  14. MKC-1

    CASI Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  15. MKC-1

    CASI Pharmaceuticals

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  16. MLN1202 Placebo

    Takeda

    Diabetic Nephropathy

    phase 2 small molecule terminated

    1 trial

  17. MMV390048 40mg

    CNS Pharmaceuticals

    Malaria

    phase 2 small molecule completed

    1 trial

  18. MOVIPREP, MaaT033, MOVIPREP Orange, poudre pour solution buvable, Placebo is an inert coated capsule with no microbiota (active substance) inside. It is composed of a mix of coloring agents and partially pre-gelatinized corn starch in Hydroxypropyl methylcellulose capsule.

    Pari Pharma GmbH

    AXIAL SPONDYLOARTHRITIS

    phase 2 small molecule active

    1 trial

  19. MP-424 (Telaprevir)

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  20. MR-130A-01

    Mylan Pharma UK

    Investigation of maintenance of ovulation inhibition after intentional application errors for indication of contraception in healthy subjects

    phase 2 small molecule active

    1 trial

  21. MSCAT-THAC Placebo, Allogeneic Mesenchymal stromal cells derived from adipose tissue thawed and cultured

    Pari Pharma GmbH

    Systemic sclerosis

    phase 2 small molecule active

    1 trial

  22. MYCOPHENOLIC ACID , PREDNISONE, MYCOPHENOLATE SODIUM, PREDNISONE, MYCOPHENOLATE SODIUM, Placebo 0 mg hard gelatin capsule size 0 and size 2, (placebo to LNP023), METHYLPREDNISOLONE , IPTACOPAN, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, LNP023, Placebo to prednisone

    Novartis Pharmaceuticals

    Lupus Nephritis Class III-IV, +/- V

    phase 2 small molecule active

    1 trial

  23. MaaT013, Placebo de MaaT013 - Major ingredients: Calcium carbonate; Xanthan gum; Alimentary colorant; E150d: caramel color; HCl;Purified water

    Pari Pharma GmbH

    Melanoma

    phase 2 small molecule active

    1 trial

  24. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Intrahepatic Cholestasis of Pregnancy

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources